Kymera secures $1.6B cash runway to 2029 and advances KT-621 Phase 2b trials
Kymera Therapeutics ended 2025 with $1.6 billion cash, securing runway into 2029, and initiated KT-579 Phase 1 dosing with data due in H2 2026. KT-621 STAT6 degrader delivered deep STAT6 degradation and clinical improvements in Phase 1b atopic dermatitis, with Phase 2b BROADEN2 and BREADTH trial data expected mid-2027 and late-2027.
1. Financial Results and Cash Position
Kymera closed 2025 with $1.6 billion cash and equivalents, ensuring operational runway into 2029 without near-term fundraising. This strong balance sheet underpins continued investment in clinical programs and discovery efforts.
2. STAT6 Degrader KT-621 Progress
In Phase 1b atopic dermatitis, KT-621 achieved deep STAT6 degradation, robust biomarker reductions and meaningful clinical improvements, matching or exceeding four-week dupilumab data. Global Phase 2b BROADEN2 (AD) and BREADTH (asthma) trials are enrolling, with anticipated data by mid-2027 and late-2027 respectively.
3. KT-579 Phase 1 Initiation
Dosing has begun in the first-in-human Phase 1 healthy volunteer trial for KT-579, the IRF5-targeting oral degrader, with top-line safety and pharmacokinetic data expected in the second half of 2026. Success could open novel treatment avenues for multiple autoimmune disorders.
4. Leadership Appointment and Webcast
Dr. Neil Graham, a seasoned biopharma executive, has joined as Chief Development Officer to lead clinical strategy and execution. Kymera will host a webcast and conference call today at 8:30 a.m. ET to discuss results and outlook.